Company intelligence
CG Oncology
Attacking Bladder Cancer for a Better Tomorrow
Biotechnology Research
Dallas, US
202 employees
Founded 2010
3 public signals
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Verified activity
Signals from CG Oncology
3 published signals
Presence & Recognition
CG Oncology is hosting a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026, at 8:00 AM ET.
Reported by CG Oncology
Research & Knowledge
CG Oncology published Part three of Urology Times' Investigator Perspectives video series featuring Mark Tyson, M.D., M.P.H., of Mayo Clinic in Arizona, focusing on Cohort C of the Phase 3 BOND-003 trial evaluating cretostimogene in patients with high-risk, BCG-unresponsive NMIBC with carcinoma in situ.
Reported by CG Oncology
Presence & Recognition
CG Oncology team members left San Diego after attending the Bladder Cancer Advocacy Network Fall Bladder Cancer Summit.
Reported by CG Oncology